What is the significance of this filing being an amendment (10-Q/A)?

An amendment to a 10-Q filing (10-Q/A) typically means that Vertex Pharmaceuticals is correcting or supplementing information that was previously filed. Investors should carefully review the amendment to understand what specific data or disclosures have been changed or added and the reasons for these changes.

Where can I find information about Vertex's revenue and profitability for the quarter?

Information regarding revenue and profitability for the quarter and six months ended June 30, 2001, can be found in the 'Condensed Consolidated Statements of Operations' located on pages 2 and 3 of the filing. For a deeper understanding of the factors influencing these results, refer to Item 2, 'Management's Discussion and Analysis of Financial Condition and Results of Operations'.

What is Vertex's financial health based on the balance sheet?

The 'Condensed Consolidated Balance Sheets' on page 1 provide a snapshot of Vertex's assets, liabilities, and equity as of June 30, 2001, and December 31, 2000. Investors should analyze the trends in working capital, debt levels, and overall equity to assess the company's financial stability.

How is Vertex managing its cash during this period?

The 'Condensed Consolidated Statements of Cash Flows' on page 4 details Vertex's cash inflows and outflows from operating, investing, and financing activities for the six months ended June 30, 2001, and 2000. This statement is crucial for understanding the company's liquidity and its ability to fund its operations and growth initiatives.

VRTX 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. (VRTX) has filed an amendment to its 10-Q filing for the period ending June 29, 2001. This report provides investors with an updated look at the company's financial performance and condition. While the filing is an amendment, it primarily refers to the previously filed financial statements for the quarter and six months ended June 29, 2001, including the consolidated balance sheets, statements of operations, and cash flows. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section for detailed insights into the company's operational results, financial condition, and future outlook, as well as the notes accompanying the financial statements for crucial accounting policies and disclosures. The amendment nature suggests a need for clarification or correction of previously submitted information. Investors are advised to review the specific changes within the amendment document, if any are detailed, alongside the original filing to fully understand any revised financial data or narrative disclosures. The report also includes sections on market risk and other corporate matters, providing a comprehensive view of the company's financial landscape during this period.

Key Highlights

1The filing is an amendment (10-Q/A) to the quarterly report for the period ending June 29, 2001, indicating potential revisions or clarifications to previously submitted financial data.
2Key financial statements included are Condensed Consolidated Balance Sheets as of June 30, 2001, and December 31, 2000.
3The report details Condensed Consolidated Statements of Operations for both the three and six months ended June 30, 2001, compared to the prior year periods.
4Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2001, and 2000 are provided.
5Item 2, Management's Discussion and Analysis (MD&A), is a critical section for investors to understand the operational performance, financial condition, and future prospects of Vertex Pharmaceuticals.
6Item 3 addresses Quantitative and Qualitative Disclosures about Market Risk, offering insights into how the company manages financial risks.
7Part II of the filing covers other information, including matters submitted to a vote of security holders and exhibits.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report (Amendment) for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions